AstraZeneca Plc’s experimental treatment anifrolumab significantly reduced disease activity in patients with the autoimmune disorder lupus in a late-stage study.
China’s Bio-Thera Solutions Ltd. won a regulatory approval for the company’s version of AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market.
Almost no health topic was off limits at Chronicon, a first-of-its kind day-long event that brought together today’s most impactful health influencers specializing in chronic health conditions for an open forum to address the needs of those living with chronic conditions and their support communities.
Despite the success Gilead Sciences has experienced with the JAK inhibitor filgotinib in rheumatoid arthritis, the medication failed to hit the mark in mid-stage trials aimed at lupus and Sjogren’s syndrome.
J&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study.
IFM Therapeutics subsidiary IFM Due and Novartis will develop a group of immunotherapies that inhibit the cGAS/STING pathway to treat a broad range of inflammatory and autoimmune diseases.
AstraZeneca’s experimental drug to treat moderate-to-severe lupus met the main goal in a late-stage trial. During 2018, anifrolumab failed to meet the primary target in the final stage of another study.
AbbVie’s Rinvoq was approved by the FDA for treating adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
Gilead Sciences Inc. and Galapagos NV announced that the Marketing Authorization Application for filgotinib – an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis – was validated and is under evaluation by the European Medicines Agency.
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.